Articles tagged with Heart Failure
A study published in Nature Medicine found that off-the-shelf wearable trackers can monitor the response to two treatments for atrial fibrillation and heart failure. The devices provided clinically useful information similar to in-person hospital assessments, with a neural network helping to analyze missing data.
Scientists have identified a critical genetic mechanism driving cardiac fibrosis and found a novel target for its reversal. The discovery sheds light on the role of transforming growth factor-beta (TGFβ) and ATP-citrate lyase (ACLY) in promoting excessive tissue scarring, providing hope for new heart failure treatments.
Researchers found that combining sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists reduces the risk of major adverse cardiovascular events and chronic kidney disease progression by 11% and 33%, respectively. The study suggests using this combination to further improve outcomes in patients with typ...
A new American Heart Association scientific statement highlights the benefits of palliative care in managing symptoms and improving quality of life for people with cardiovascular disease. Palliative care complements standard cardiovascular care by reducing physical symptoms, emotional distress, and assisting patients in making decision...
A recent review of studies on heart failure patients suggests that reducing salt intake has no clinical benefits and may even be counterproductive. Moderate to strict salt restriction was linked with improved quality of life but not mortality or hospitalization rates among patients with heart failure.
The WVU researchers developed a non-invasive, at-home sleep apnea detection device that uses artificial intelligence technology to measure oxygen levels in the blood. Early detection can help prevent worsening of underlying comorbid conditions and reduce healthcare costs, according to Dr. Sunil Sharma.
Researchers found that hospitals that implemented standardized protocols from the American Heart Association and American Stroke Association saw significant reductions in stroke treatment times. The protocols, which include specific limits on time between symptom onset and hospital arrival, helped medical teams respond more quickly to ...
Women with obesity-related heart failure experienced greater weight loss and improved HF symptoms compared to men. Semaglutide improved HF-related symptoms, physical limitations, exercise function, reduced inflammation, and lower blood pressure across both sexes.
Researchers created an integrated cellular map of a mouse model heart, pinpointing cells and pathways involved in fibrosis. The study identified myofibroblasts as the major drivers of scarring, but also discovered a 'matrifibrocyte' form that may prevent scar resolution.
Researchers used a model of the heart and lung system to simulate how microgravity could affect space tourists with underlying health issues, such as heart conditions. The study found that entry into microgravity increases cardiac output in all individuals, but for heart failure patients, this increase is accompanied by a dangerous ris...
Research published in the European Heart Journal found that women diagnosed with perinatal depression are more likely to develop cardiovascular disease. The study included data from around 600,000 women and found a strong link between perinatal depression and risks of high blood pressure, ischemic heart disease, and heart failure.
A study of over 10,000 US adults found a strong association between pro-inflammatory diets and elevated NT-proBNP levels, indicating potential increased cardiovascular risk. The research suggests that dietary inflammatory index may be an important factor in heart failure biomarker levels.
Researchers found a significant association between carpal tunnel syndrome and the risk of developing heart failure and amyloidosis. Individuals with carpal tunnel syndrome were at a 13% higher risk of heart failure and a threefold higher risk of amyloidosis compared to those without the condition.
A study by the University of Michigan Health Frankel Cardiovascular Center found that only 23% of heart attack patients received dietary counseling within 90 days of hospitalization. Nutrition counseling, often provided by registered dietitian nutritionists, may reduce cardiovascular risk for patients.
A mouse study found that heart failure with preserved ejection fraction (HFpEF) differs between male and female mice, with females exhibiting altered heart filament proteins and males showing slowed calcium removal. This may lead to different treatment strategies for women compared to men with HFpEF.
Researchers found that 6% of patients with heart failure progressed to dialysis within a year, highlighting the need for integrating heart and kidney care. The study emphasizes prioritizing kidney function assessment in all patients with heart failure and promoting systemic changes to manage both conditions simultaneously.
A new study reveals that heart failure leaves a 'stress memory' in hematopoietic stem cells, which can lead to recurrent heart failure and other health issues. The researchers propose improving TGF-β levels as a new avenue for treating recurrent heart failure.
The conference will feature 12 late-breaking clinical trials and science presentations on transcatheter aortic valve replacement, mitral and tricuspid devices and techniques. Data from these trials will guide the selection of patients who will benefit most from procedures and define optimal treatment strategies.
A team of researchers led by Dr. Ahmed discovered that two FDA-approved antibiotics can induce heart regeneration in mammals, showing promise for treating heart failure. The study found that the antibiotics improved cardiac output and reduced fibrotic scar tissue, suggesting a potential new therapy.
Researchers review cell-based therapies for comprehensive sepsis management, highlighting the potential of mesenchymal stem cells and innate immune cells like macrophages. The review also emphasizes the need for further studies on optimal dosage, administration routes, and storage methods to maximize efficacy and safety.
A new study has improved the detection of heart failure in women, allowing for earlier diagnosis and potentially life-saving treatment. The research used magnetic resonance imaging to fine-tune how pressures inside the heart are measured, increasing accuracy by 16.5% for female patients.
Researchers found beneficial effects of Sacubitril/Valsartan in reducing inflammation, cardiac fibrosis, and preventing arrhythmias post-MI. The drug has shown promise in mitigating these effects and promoting healthier scar formation.
A clinical trial found that aficamten significantly increased maximum oxygen use in patients with obstructive hypertrophic cardiomyopathy. This improvement enables patients to perform everyday tasks more easily, such as walking and household chores. Researchers believe aficamten has promise as a treatment for this condition.
Cardiovascular biomarkers strongly associated with cardiovascular events and mortality. Adding biomarkers to established risk factors improved heart failure and mortality prediction, but only slightly enhanced atherosclerotic disease risk prediction.
The V142I transthyretin variant is associated with substantial risk for heart failure hospitalization and death in Black individuals, particularly those with reduced ejection fraction. Further investigation into the complex interplay between the variant, ancestry, social determinants of health, and biological factors is warranted.
Researchers studied cardiothoracic surgeons and found that accumulating failures triggers forces both increasing the opportunity to learn and decreasing motivation. This effect is higher for surgeons with lower perceived abilities to learn.
Researchers developed novel glyceraldehyde derivatives from empagliflozin with improved cardiomyocyte protective effects and reduced cytotoxicity. These compounds significantly inhibited NHE1 activity, maintaining intracellular ion homeostasis and exhibiting favorable safety profiles.
A team of researchers at the University of Houston has identified AKAP12 as a promising target for treating heart failure through precision pharmacology. Increased levels of AKAP12 in cardiac myocytes accelerate cardiac dysfunction, but inhibiting PDE8A can reverse this effect and improve contractility.
A new implantable cardiac pump could revolutionize heart transplant care for children, allowing them to wait at home instead of in the hospital. The device performed well in a feasibility trial, with six out of seven children ultimately undergoing transplants and one child's heart recovering on its own.
A recent Finnish study discovered that high levels of sedentary behavior and low physical activity in children are associated with a higher cardiac workload and increased risk of heart disease in adolescence. Regular moderate to vigorous physical activity from childhood can help prevent these issues.
Jeffrey W. Moses, MD, is recognized for advancing the field of interventional cardiovascular medicine through technical excellence and leadership. Dr. Moses has performed over 20,000 interventional procedures and made significant contributions to clinical research and educational activities in interventional vascular therapy.
Heart failure affects younger populations with high comorbidities like diabetes and hypertension. In-hospital mortality ranges from 2.8% to 8.4%, and one-year mortality is higher with re-hospitalization being very common.
Researchers found that over 130,000 people in Denmark live with atrial fibrillation, with a 20% increase in new cases each year. The study reveals heart failure is the most common complication, with a risk of death twice as high as stroke after diagnosis.
A Weill Cornell Medicine study found that over 15-fold more Haitians have early-onset heart failure than previously thought, with elevated blood pressure being the leading risk factor. The research suggests a shift in focus to early prevention and treatment of cardiovascular diseases in low-income countries.
A multicenter study found that dapagliflozin improves diuresis and reduces hospital stays in patients with acute heart failure. The drug was shown to be safe and effective when initiated during early hospitalization, leading to faster discharge times.
Contemporary US heart failure mortality rates have surpassed those in 1999 due to reversals from 2012 to 2021. The COVID-19 pandemic may have accelerated these increases, partly due to healthcare access limitations.
Atrial fibrillation is more common and deadly among young Americans than previously believed, a new study found. The study of over 67,000 patients under 65 years old showed higher rates of hospitalization, stroke, heart attack, comorbidity, and mortality compared to their peers without Afib.
The American Association for Thoracic Surgery (AATS) and Cardiovascular Research Foundation (CRF) will collaborate on the development of New York Valves 2024, focusing on advances in surgical approaches and techniques in valve disease. The summit will feature expert discussions, live-case demonstrations, and hands-on training.
Researchers found that reticulon 3 (RTN3) is downregulated in left ventricular tissue of patients with heart failure after myocardial infarction. RTN3 knockout alleviated cardiac dysfunction after MI, while overexpression decreased systolic function.
Researchers found that accelerated aging biology in the placenta contributes to peripartum cardiomyopathy (PPCM), a rare form of pregnancy-related heart failure. The study identifies underlying aging-related biology contributing to maternal heart failure and provides evidence from both patients and animal models.
Scientists at CNIC have identified mechanisms by which anthracyclines damage the hearts of cancer patients, leading to cardiac injury. The study suggests that a protein-enriched diet may prevent muscle atrophy caused by anthracycline chemotherapy.
Over five RSV seasons, researchers found that nearly one-quarter of hospitalized adults aged 50+ experienced an acute cardiac event, mostly heart failure. The risk of severe outcomes was nearly twice as high in patients with cardiac events compared to those without.
The article discusses the evolving role of transcatheter tricuspid valve edge-to-edge repair in treating severe tricuspid regurgitation. Preliminary results show promising outcomes, making it a feasible and effective option for high-risk surgical patients.
Dr. Himabindu Vidula will lead the American College of Cardiology's (ACC) Board of Governors for a one-year term, focusing on membership engagement and community outreach. Her goal is to strengthen how the ACC serves its members and the broader cardiovascular care community.
Researchers developed a new method to detect heart failure using smartphones by analyzing heart movement. The technology has been shown to be accurate in identifying patients with heart failure, offering potential benefits for remote monitoring and treatment.
A new study found that high-dose influenza vaccine significantly improved humoral response in patients with heart failure or prior myocardial infarction. Vaccination remains crucial in preventing influenza-related complications in high-risk populations.
A meta-analysis of 11 trials involving 78,607 patients found a 9% reduction in major adverse cardiovascular events (MACE) and a 14% reduction in cardiovascular death with SGLT2 inhibitors. The analysis showed consistent effects across patient groups and subgroups.
A new study found that inter-atrial shunts improve symptoms and outcomes in heart failure patients with reduced left ventricular ejection fraction (LVEF), but worsen outcomes in those with preserved LVEF. The device reduces high pressures in the left atrium, causing shortness of breath and hospitalizations.
Two anti-inflammatory molecules, TGFβ1 and HpTGM, reduce the inflammatory response within the injured heart and scarring. Treatment with these proteins at the time of reperfusion reduces infarct size and mature scar size.
New York Valves: The Structural Heart Summit is a world-class educational experience for the field of structural heart interventions. The summit will showcase advanced techniques, evidence-based medicine, and live-case demonstrations, offering attendees an unparalleled opportunity to explore the newest techniques and technologies.
People who use e-cigarettes are significantly more likely to develop heart failure compared with those who have never used them. The study found a substantial association between e-cigarette use and an increased risk of heart failure, especially for heart failure with preserved ejection fraction.
Among a sample of over 3,100 people with heart disease, 89% consumed more than the recommended daily maximum of 1,500 mg of sodium, and study participants on average consumed more than twice this amount. Limiting sodium intake is crucial for reducing major adverse cardiovascular events.
University of Virginia researchers have identified a single gene on the Y chromosome that can account for the disease-promoting effects of Y chromosome loss. This discovery provides new avenues for understanding the causes of heart disease and could lead to a treatment for men with Y chromosome loss.
Research highlights treating anxiety and depression in people with heart disease can significantly reduce emergency room visits, hospitalizations, and even death. The study found that talk therapy and antidepressant medications improved heart outcomes among those with blocked arteries or heart failure.
A multi-institutional team is creating innovative technologies to reduce complications associated with left ventricular assist devices (LVADs), including infection, thrombosis, stroke, and bleeding. The new LVAD will deliver a physiological response to changes in the recipient's activity levels using a 'smart' Maglev drive technology.
Research found that certain patterns of pregnancy history, including early deliveries and multiple hypertensive disorders, are associated with high risk of heart attack and stroke. Others with fewer or no complications have lower risk, suggesting other factors may also play a role in predicting cardiovascular disease mortality.
Researchers found that Black individuals carrying genetic variants in the Titin, TTN gene have a high risk of developing atrial fibrillation, heart failure, and dilated cardiomyopathy. The study used data from the All of Us Research Program to examine the role of these genetic mutations in African ancestry individuals.
A multicenter randomized trial showed a paclitaxel-coated balloon to be superior to an uncoated balloon in preventing target lesion failure in patients with coronary in-stent restenosis. The study included 600 patients and demonstrated the effectiveness of paclitaxel-coated balloons as a treatment option.
Researchers at the University of Virginia Health System are developing a technique to 'paint' tiny nanoparticles on transplanted veins to prevent blockages, potentially sparing patients from repeated surgeries. This approach could significantly reduce the number of vascular reconstructions performed annually in the US.
Researchers aim to address LVAD shortcomings, reducing blood damage and clotting risk through innovative designs and coatings. A novel flexible stented blood inlet and slippery hydrophilic coatings will be used to prevent flow stasis and clot formation.